Leerink Partners Starts Neurocrine Bio. (NBIX) at Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Nasdaq falls as Alphabet set for record loss amid AI spending woes
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $145.92 +0.27%
Rating Summary:
31 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 23 | New: 16
Rating Summary:
31 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 23 | New: 16
Join SI Premium – FREE
Leerink Partners analyst Marc Goodman initiates coverage on Neurocrine Bio. (NASDAQ: NBIX) with a Market Perform rating and a price target of $110.00.
For an analyst ratings summary and ratings history on Neurocrine Bio. click here. For more ratings news on Neurocrine Bio. click here.
Shares of Neurocrine Bio. closed at $105.41 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Seaport Global Securities Starts Anthropic (ANT), Defers Offering Rating
- HSBC Upgrades FedEx (FDX) to Buy
- Northland Starts Digital Turbine (APPS) at Outperform, 'Proven Turnaround'
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
